Fatal interstitial lung disease associated with AZD9291

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) is a major cause of cancer-related mortality.
• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like AZD9291 are standard treatments for specific NSCLC subtypes.
• Drug-induced interstitial lung disease (ILD) is a potential, though infrequent, adverse event associated with targeted cancer therapies.

Observation:

• A patient with NSCLC was treated with AZD9291, a third-generation EGFR-TKI.
• The patient subsequently developed interstitial lung disease (ILD).
• The clinical course of the ILD was severe, ultimately leading to patient mortality.

Findings:

• This case highlights a rare but critical adverse event associated with AZD9291 treatment.
• The development of ILD in the context of EGFR-TKI therapy underscores the need for vigilant monitoring.
• The fatal outcome emphasizes the potential severity of drug-induced ILD.

Implications:

• Improved awareness and early recognition of AZD9291-induced ILD are crucial for patient management.
• Further research into the mechanisms and risk factors for ILD in patients receiving EGFR-TKIs is warranted.
• This case contributes valuable knowledge for oncologists and pulmonologists managing NSCLC patients on AZD9291 therapy.